Commission Implementing Decision (EU) 2016/1659 of 13 September 2016 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2016) 5748) (Text with EEA relevance)

Implementing Decision (EU) 2016/1659 · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Annexes I and II to Decision 2008/911/EC are amended in accordance with the Annex to this Decision.

Article 2

This Decision is addressed to the Member States.

Supplementary provisions

ANNEXSupplementary provisions

ANNEX Decision 2008/911/EC is amended as follows: (1) In Annex I, the following substance is inserted after Hamamelis virginiana L. : ‘ Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and/or other species of Melaleuca , aetheroleum’; (2) In Annex II, the following is inserted after the entry Hamamelis virginiana L. : ‘UNION LIST ENTRY ON MELALEUCA ALTERNIFOLIA (MAIDEN AND BETCH) CHEEL, M. LINARIIFOLIA SMITH, M. DISSITIFLORA F. MUELLER AND/OR OTHER SPECIES OF MELALEUCA , AETHEROLEUM Scientific name of the plant Melaleuca alternifolia (Maiden and Betch) Cheel, M. linariifolia Smith, M. dissitiflora F. Mueller and other species of Melaleuca Botanical family Myrtaceae Common name in all EU official languages of herbal preparation BG (bălgarski): Чаено дърво, масло CS (čeština): silice kajeputu střídavolistého DA (dansk): Tetræolie DE (Deutsch): Teebaumöl EL (elliniká): Μελαλεύκης αιθέριο έλαιο EN (English): Tea tree oil ES (español): Melaleuca alternifolia, aceite esencial de ET (eesti keel): teepuuõli FI (suomi): teepuuöljy FR (français): Mélaleuca (arbre à thé) (huile essentielle de) HR (hrvatska): eteričnog ulje australijskog čajevca HU (magyar): Teafa-olaj IT (italiano): Melaleuca essenza LT (lietuvių kalba): Arbatmedžių eterinis aliejus LV (latviešu valoda): Tējaskoka ēteriskā eļļa MT (Malti): Żejt tal-Melaleucae NL (Nederlands): Theeboomolie PL (polski): Olejek eteryczny drzewa herbacianego PT (português): Óleo esencial de melaleuca RO (română): Melaleuca (arbore de ceai) (ulei esențial) SK (slovenčina): Silica melaleuky SL (slovenščina): eterično olje melalevke SV (svenska): Teträdsolja NO (norsk): Tetreolje Herbal preparation Essential oil European Pharmacopoeia monograph reference 01/2008:1837 Indications Indication (a) Traditional herbal medicinal product for treatment of small superficial wounds and insect bites. Indication (b) Traditional herbal medicinal product for treatment of small boils (furuncles and mild acne). Indication (c) Traditional herbal medicinal product for the relief of itching and irritation in cases of mild athlete's foot. Indication (d) Traditional herbal medicinal product for symptomatic treatment of minor inflammation of the oral mucosa. The product is a traditional herbal medicinal product for use in specified indication exclusively based upon long-standing use. Type of tradition European. Specified strength Please see ‘Specified posology’. Specified posology Indication (a) Adolescents, adults and elderly Single dose 0,03-0,07 ml of undiluted essential oil to be applied to the affected area using a cotton bud 1-3 times daily. Liquid preparations containing 0,5 % to 10 % of essential oil to be applied to the affected area 1-3 times daily. Indication (b) Adolescents, adults and elderly Single dose Oily liquid or semi-solid preparations containing 10 % of essential oil to be applied to the affected area 1-3 times daily, or 0,7-1 ml of essential oil stirred into 100 ml of lukewarm water to be applied as an impregnated dressing to the affected areas of skin. Undiluted essential oil to be applied to the boil using a cotton bud 2-3 times daily. Indication (c) Adolescents, adults and elderly Single dose Oily liquid or semi-solid preparations containing 10 % of essential oil to be applied on the affected area 1-3 times daily. 0,17-0,33 ml of essential oil in an appropriate volume of warm water to cover the feet. Soak feet for 5-10 minutes daily. Undiluted essential oil to be applied to the affected area using a cotton bud 2-3 times daily. Indication (d) Adolescents, adults and elderly 0,17-0,33 ml of essential oil to be mixed in 100 ml of water for rinse or gargle several times daily. The use in children under 12 years of age is not recommended (see section ‘Special warnings and precautions for use’). Route of administration Indications (a), (b) and (c) Cutaneous use Indication (d) Oromucosal use. Duration of use or any restrictions on the duration of use Indication (a) If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indications (b) and (c) Not to be used for more than 1 month. If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication (d) If the symptoms persist longer than 5 days during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance or to colophony. Special warnings and precautions for use The use in children under 12 years of age has not been established due to lack of adequate data. If a rash develops, discontinue use. Not to be used orally or as inhalation. Not to be used in eyes or ears. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication (a) If fever or signs of exacerbating skin infection are observed, a doctor or a qualified health care practitioner should be consulted. Indication (b) In cases of severe acne a doctor or a qualified health care practitioner shall be consulted. Indication (c) For the eradication of fungal infection a doctor or a qualified health care practitioner shall be consulted. Indication (d) Not to be swallowed. Interactions with other medicinal products and other forms of interaction None reported. Fertility, pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Adverse skin reactions including smarting pain, mild pruritus, burning sensation, irritation, itching, stinging, erythema, oedema (contact dermatitis) or other allergic reactions have been reported. The frequency is not known. Burn-like skin reactions have been reported. The frequency is rare (< 1/1 000). If other adverse reactions not mentioned occur, a doctor or a qualified health care practitioner should be consulted. Overdose Cutaneous use: None reported. Oromucosal use: Accidental overdose may cause central nervous system depression and muscle weakness. However, in adults these symptoms generally resolve within 36 hours. If ingestion occurs, the patient should be monitored and standard supportive treatment applied as required. In children, ingestion of tea tree oil is a medical emergency requiring immediate hospital treatment and respiratory support. Pharmaceutical particulars (if necessary) Store in air-tight containers, protected from light and heat. Proper storage and handling are needed to avoid the formation of oxidation products which have greater potential for skin sensitisation. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience (if necessary for the safe use of the product) Not applicable.’

Other acts of the same type

Commission Decision (EU) 2019/700 of 19 December 2018 on the State Aid SA.34914 (2013/C) implemented by the United Kingdom as regards the Gibraltar Corporate Income Tax Regime (notified under document C(2018) 7848)Commission Implementing Decision of 17 December 2018 on the publication in the Official Journal of the European Union of the application for registration of a name referred to in Article 49 of Regulation (EU) No 1151/2012 of the European Parliament and of the Council (‘Zagorski mlinci’ (PGI))Council Decision (CFSP) 2018/2007 of 17 December 2018 amending Joint Action 2008/851/CFSP on a European Union military operation to contribute to the deterrence, prevention and repression of acts of piracy and armed robbery off the Somali coast Council Decision (CFSP) 2018/2008 of 17 December 2018 amending and extending Decision 2014/219/CFSP on the European Union CSDP Mission in Mali (EUCAP Sahel Mali)Council Decision (CFSP) 2018/2009 of 17 December 2018 amending and extending Decision 2013/233/CFSP on the European Union Integrated Border Management Assistance Mission in Libya (EUBAM Libya)Council Decision (CFSP) 2018/2012 of 17 December 2018 amending Decision (CFSP) 2015/1333 concerning restrictive measures in view of the situation in Libya Commission Implementing Decision (EU) 2018/2021 of 17 December 2018 amending Implementing Decision (EU) 2015/348 as regards the consistency of the revised targets in the key performance area of cost-efficiency included in the amended national or functional airspace block plans submitted by Portugal and Romania (notified under document C(2018) 8489) (Text with EEA relevance.)Commission Decision (EU) 2018/2022 of 17 December 2018 drawing up a list of qualified experts for the Boards of Appeal of the European Union Agency for Railways (notified under document C(2018) 8561)Commission Implementing Decision (EU) 2018/2023 of 17 December 2018 on amending Implementing Decision (EU) 2017/1984 determining, pursuant to Regulation (EU) No 517/2014 of the European Parliament and of the Council on fluorinated greenhouse gases, reference values as regards reference values for the period from 30 March 2019 to 31 December 2020 for producers or importers established within the United Kingdom, which have lawfully placed on the market hydrofluorocarbons from 1 January 2015, as reported under that Regulation (notified under document C(2018) 8801)Commission Decision (EU) 2019/1144 of 17 December 2018 on the State aid SA.36086 (2016/C) (ex 2016/NN) implemented by Romania for Oltchim SA (notified under document C(2018) 8592) (Text with EEA relevance.)Commission Decision (EU) 2018/1996 of 14 December 2018 laying down internal rules concerning the provision of information to data subjects and the restriction of certain of their rights in the context of the processing of personal data for the purpose of trade defence and trade policy investigations Commission Implementing Decision (EU) 2018/2013 of 14 December 2018 on the identification of 1,7,7-trimethyl-3-(phenylmethylene)bicyclo[2.2.1]heptan-2-one (3-benzylidene camphor) as a substance of very high concern pursuant to Article 57(f) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (Text with EEA relevance.)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview